Dutch scientists plan to compare the ability of FDG-PET and CT scans to predict whether tumors in patients with curable esophageal cancer will respond to neoadjuvant chemoradiotherapy. FDG-PET is capable of measuring the metabolic changes in tumor tissue, which earlier data have found to be an accurate predictor of tumor response.

Related Summaries